Unidad de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, Sevilla, España; Departamento de Microbiología, Universidad de Sevilla, España; Instituto de Biomedicina de Sevilla IBIS, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Sevilla, España; Red Española de Investigación en Patología Infecciosa (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, España.
Red Española de Investigación en Patología Infecciosa (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, España; Unidad de Gestión Clínica de Microbiología, Hospital Universitario Reina Sofía, Córdoba, España; Departamento de Microbiología, Universidad de Córdoba, España; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Córdoba, Córdoba, España.
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Apr;38(4):150-154. doi: 10.1016/j.eimc.2019.06.009. Epub 2019 Aug 7.
The aim of this study was to determine the antimicrobial resistance rates and their evolution in clinical isolates of Pseudomonas aeruginosa causing invasive infections in the south of Spain between 2012 and 2017.
Retrospective study consisting of the collection of microbiological data from 20 hospitals (14 from Andalucía, 5 from Extremadura and 1 from Ceuta) between 2012 and 2017. The main variables studied were the antimicrobial susceptibility testing system used, interpretation criteria (CLSI or EUCAST) and the rate or percentage of resistant isolates.
The most widely used antimicrobial susceptibility testing system was MicroScan (58%). The global resistance rates varied between 25% (ciprofloxacin) and 4% (colistin) using EUCAST, and between 19% (ciprofloxacin and imipenem) and 3% (amikacin) using CLSI. The antimicrobial resistance rates were relatively stable throughout the period 2012-2017. 14% of isolates were MDR and 7% were XDR. Respiratory isolates were more resistant, particularly to ciprofloxacin and colistin, than isolates from urine or blood.
The antimicrobial resistance rates in P. aeruginosa are not particularly high in the south of Spain. The highest resistance rates were observed with ciprofloxacin, piperacillin/tazobactam and meropenem, whereas the more active antimicrobials were colistin, tobramycin and amikacin. The highest resistance rates were seen in respiratory isolates. In general, the resistance rates remained stable during the study period for most of the antimicrobials studied.
本研究旨在确定 2012 年至 2017 年间西班牙南部引起侵袭性感染的铜绿假单胞菌临床分离株的抗菌药物耐药率及其变化趋势。
这是一项回顾性研究，收集了 2012 年至 2017 年间 14 家来自安达卢西亚、5 家来自埃斯特雷马杜拉和 1 家来自休达的医院的微生物学数据。主要研究变量包括使用的抗菌药物敏感性测试系统、解释标准（CLSI 或 EUCAST）以及耐药分离株的比例或百分比。
使用最广泛的抗菌药物敏感性测试系统是 MicroScan（58%）。使用 EUCAST，铜绿假单胞菌的全球耐药率在 25%（环丙沙星）至 4%（黏菌素）之间变化，而使用 CLSI，耐药率在 19%（环丙沙星和亚胺培南）至 3%（阿米卡星）之间变化。2012-2017 年间，抗菌药物耐药率相对稳定。14%的分离株为 MDR，7%为 XDR。与尿液或血液分离株相比，呼吸道分离株的耐药性更高，特别是对环丙沙星和黏菌素。
在西班牙南部，铜绿假单胞菌的抗菌药物耐药率并不特别高。最高的耐药率见于环丙沙星、哌拉西林/他唑巴坦和美罗培南，而更有效的抗菌药物是黏菌素、妥布霉素和阿米卡星。呼吸道分离株的耐药率最高。总的来说，在研究期间，大多数研究的抗菌药物耐药率保持稳定。
